Professional Documents
Culture Documents
10]
Review Article
Dick B. S. Brashier, Anjan Khadka1, Tejus Anantharamu, Ashok Kumar Sharma, A. K. Gupta,
Sushil Sharma, N. Dahiya
Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India, 1Department of Pharmacology, Nepalese Army
Institute of Health Sciences, Kathmandu, Nepal
ABSTRACT
This is an open access article distributed under the terms of the Creative Commons
DOI: AttributionNonCommercialShareAlike 3.0 License, which allows others to remix,
10.4103/0976-500X.162013 tweak, and build upon the work noncommercially, as long as the author is credited and
the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com
loss, in individuals with underlying renal or hepatic disease These particles have an average diameter of 2.5 m,
that precludes oral glucoselowering agents, or in hospitalized with >90% being in range of 0.55.8 m(suitable for
or acutely ill individuals. Insulin therapy is ultimately required inhalation as will be delivered into alveoli without
by almost all individuals with type2 DM because of the hindrance)
progressive nature of the disorder and the relative insulin The high solubility of these particles at pH>6 matches
deficiency that develops in patients with longstanding with the prevailing physiological pH in lungs that
diabetes.[4] helps in easy dissolution and absorption into systemic
circulation.
Insulin may be administered intravenously, intramuscularly,
or subcutaneously. The major drawback of currently available
formulations of insulin is that they have to be injected and PHARMACOKINETICS
moreover fail to mimic physiological postprandial insulin
delivery into systemic circulation. [5] There have been It is ultrarapidacting insulin which mimics a linear
continuous efforts to find new insulin formulations and new doserelated pharmacokinetic profile in patients of type1 and 2
routes of administration so that it mimics physiological DM.[13] Maximum plasma drug concentration reached between
secretion of pancreatic betacells.[6] Oral insulin is currently 10 and 15min(Tmax) which is very early compared to regular
being studied in type1 diabetes prevention with promising insulin or other rapidly acting insulin analogues(2045min).
results and inhalational insulin has been recently approved This is important as it mimics firstphase insulin release after
by Food and Drug Administration(FDA) on 27 June 2014 food seen in nondiabetic individuals. Duration of action is
for glycemic control in adults with type1 and type2 DM.[79] around 23 hrs.[1315] 60% of the inhaled drugs gets deposited
in the lungs.[14] Inhaled insulin is designed to be used within
Inhalational insulin has been developed by MannKind 20min of beginning a meal [Figure1].
Corporation and it is a novel rapidacting inhaled insulin
available as Afrezza with a drug device in the form of small
DEVICE SYSTEM
easy to use inhaler and the inhalational powder as singleuse
cartridges.[9] The idea of making inhalation as the route of
Breathpowder inhaler is used which can be reused after
delivering insulin is not entirely new; seven years ago when
changing the cartridge for 15days. The procedure has been
Exubera(Pfizer Incs) received FDA approval it was thought to
made very simple to enhance the compliance in which the
be a great achievement, but quickly faded out as concerns were
cartridge of powdered insulin is placed, then close the device
raised about its safety regarding its effect on lung function, its
and with a single breath the powder will be inhaled; later open
heavy price tag and bulky inhaler.[10]
the device, remove the cartridge out and then discard.[16]
Various strategies are being worked out to reduce the gap
This device offers various advantages:[13,16,17]
between physiological and nonphysiological insulin release
The device is small and easy to carry along
so as to reduce the complications. Pulmonary route of insulin
No need of synchronizing with the inhalation as this device
delivery appears to be a feasible option to enhance this
is designed in such a way that it senses and gets activated
synchronization as lungs with thin epithelium, rich blood
with inhalation on its own
supply and a vast absorbing surface help in rapid absorption
Effectively protects the powdered insulin from getting
of insulin delivered to it.[5,1114]
affected by moisture
Reusable
ISSUE WITH PULMONARY DELIVERY OF
INSULIN
The idea of pulmonary delivery of insulin has passed various
hurdles. All the belowmentioned factors favor inhaled
insulin(Afrezza) than the earlier version Exubera.[5,13,14]
The preparation of freezedried powder insulin
in a stable form of micro particles (Bis3, 6
(4fumarylaminobutyl)2, 5diketopiperazine or FDKP)
as excipient which translates into microcrystalline
plates under slightly acidic conditions onto which
insulin can be adsorbed. FDKP is an inert excipient and
is absorbed but not metabolized and will be excreted
via urine Figure 1: Insulin inhaler[20]
Inhalational insulin system uses flow balance concept. involving 500patients of type1 DM, glycemic control was
The powder placed in the cartridge has to be broken up and equal among Afrezza and injected rapidly acting insulin group,
dispersed (deagglomerated) before delivery into lungs. The but the Afrezza group had less incidence of hypoglycemia
air which flows through the device initiates this process and probably due to rapid and short duration of action.[20,21]
lifts all the powder in the cartridge to reach the exit port; but
there is a bypass channel carrying air which also reaches the A 52week randomized, openlabel, parallelgroup
exit port and intersects the air coming from mouthpiece and study evaluating the safety and efficacy of longacting
completes the process of deagglomeration.[13,14,17,1820] insulin+prandial TI(Technosphere Insulin) versus a twice
daily injection of premixed insulin in patients of type2 DM
Inhalational insulin is available in two strengths[Figures1 and 2] showed similar and noninferior results.[16,17,20]
in foil packages. One foil package consists of two blister
cards and there are five strips per blister card. Each strip It is not a substitute for longacting insulin. It must be used
contains three cartridges. It is administered using a single in combination with longacting insulin in patients with
inhalation per cartridge. Cartridge should be stored at 28C type1 diabetes, and it is not recommended for the treatment
(3646F).[13,15,1820] [Figures2-4]. of diabetic ketoacidosis(DKA) as trials suggest an increased
incidence of DKA in patients on Afrezza. It is better not to
be used in smokers as there is a possible risk of reduction in
CLINICAL EFFICACY lung function.[17,20]
A study showed that the after injecting 60 U of TI(Technosphere
insulin=Afrezza) in patients of type2 DM, the maximal ADVERSE EFFECTS
suppression of postprandial endogenous glucose production
occurred within 45min compared to 10 U of SC rapidly acting The most common adverse reactions include hypoglycemia,
insulin analogs.[16,17,19,20] cough, throat pain and irritation. There is some evidence